Rutgers University has announced a pledge of $10 million over two years from an anonymous donor to help advance the treatment of patients with rare cancers that don't respond to standard therapies.
Part of the $1 billion Rutgers, Our Future campaign, the gift will help strengthen the university's precision medicine practice, which is designed to identify genetic abnormalities that make tumors cancerous and use that information to fine-tune treatment for cancer patients, including those at Rutgers' Cancer Institute of New Jersey. The gift also includes support for advanced genomic analyses of cancers at the Rutgers Human Genetics Institute of New Jersey.
The gift also will provide $1 million for an endowment to support cancer biology curriculum development within the university’s Department of Genetics and will fund two new faculty positions, one of which will be an endowed chair in genetics.
"We will be able to analyze patients' tumors — their individual tumors — in a way we never could before," said CINJ director Robert DiPaola. "We will do that by bringing together expertise across many disciplines at Rutgers, from physicians who take care of patients to laboratories that do research on genetic abnormalities."